SG Americas Securities LLC Sells 60,709 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

SG Americas Securities LLC lowered its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 64.9% during the 1st quarter, Holdings Channel reports. The fund owned 32,806 shares of the company’s stock after selling 60,709 shares during the period. SG Americas Securities LLC’s holdings in Amphastar Pharmaceuticals were worth $643,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AMPH. TD Asset Management Inc grew its position in shares of Amphastar Pharmaceuticals by 1.6% during the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock valued at $52,571,000 after acquiring an additional 31,160 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Amphastar Pharmaceuticals by 2.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,799,685 shares of the company’s stock valued at $48,196,000 after purchasing an additional 44,020 shares during the period. State Street Corp raised its holdings in shares of Amphastar Pharmaceuticals by 2.1% during the fourth quarter. State Street Corp now owns 1,531,786 shares of the company’s stock valued at $41,021,000 after acquiring an additional 31,044 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 3.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock valued at $37,344,000 after purchasing an additional 40,536 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Amphastar Pharmaceuticals by 41.6% during the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock valued at $33,134,000 after purchasing an additional 363,216 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on AMPH shares. Piper Sandler restated a “neutral” rating and issued a $21.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Zacks Research cut Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, June 22nd. Finally, Bank of America reiterated an “underperform” rating and set a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Five equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $22.00.

Amphastar Pharmaceuticals Stock Up 2.5%

Shares of NASDAQ:AMPH traded up $0.48 during trading hours on Tuesday, hitting $20.09. The company’s stock had a trading volume of 15,465 shares, compared to its average volume of 543,650. Amphastar Pharmaceuticals, Inc. has a 52 week low of $16.65 and a 52 week high of $31.26. The firm’s fifty day moving average price is $19.67 and its 200 day moving average price is $22.60. The company has a market capitalization of $885.99 million, a price-to-earnings ratio of 12.10, a P/E/G ratio of 3.86 and a beta of 0.89. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.The business had revenue of $171.17 million for the quarter, compared to analysts’ expectations of $173.46 million. As a group, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.41 EPS for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.